1 Intrapleural administration of MPM cells expressing tiss
2 In conclusion, the
intrapleural administration of TGF-beta2 produced excell
3 We hypothesize that
intrapleural administration of TGF-beta2 would (1) produ
4 MPM cells promotes tumor cell apoptosis, and
intrapleural EPCR gene therapy suppresses MPM progressio
5 Intrapleural fibrin precedes visceral-parietal pleural a
6 Intrapleural fibrinolysis with urokinase or alteplase fa
7 ed fluid is key to successful treatment, but
intrapleural fibrinolytic therapy did not improve outcom
8 Intrapleural HO-1 induction inhibited PMC migration afte
9 vel than did the fluid that results from the
intrapleural injection of 10 mg/kg doxycycline or 400 mg
10 Intrapleural injection of Ad.EPCR into mice with an esta
11 i-inflammatory agents, tube thoracostomy, or
intrapleural injection of sclerosing agents.
12 One group of rabbits received an
intrapleural injection of talc (400 mg/kg) and an intram
13 induce less inflammation when compared with
intrapleural injection of talc.
14 Intrapleural injection of TGF-beta(2) induced a dose-dep
15 asis of this study we conclude that a single
intrapleural injection of TGF-beta(2) induces pleurodesi
16 A single
intrapleural injection of TGF-beta(2) may produce a pleu
17 The
intrapleural injection of TGF-beta(2) resulted in a dose
18 Intrapleural injection of TGF-beta2 produced effective p
19 Intrapleural injection of the larger doses of TGF-beta(2
20 e present study was to determine whether the
intrapleural injection of transforming growth factor bet
21 Single
intrapleural injections of TGF-beta(2) at doses of 5.00
22 treated with thoracostomy tube placement and
intrapleural instillation of either urokinase or altepla
23 The optimal role of
intrapleural L-NDDP therapy currently remains to be dete
24 Intrapleural L-NDDP therapy in this patient population i
25 Intrapleural loculation can increase morbidity in hemoth
26 On day 7 a single dose of
intrapleural LTA-T (increasing in each patient) was admi
27 The toxic effects of
intrapleural LTA-T seem to be mild and favourable when c
28 tricular end-systolic pressure) of increased
intrapleural pressure in dilated ventricles.
29 hallenge were also correlated with increased
intrapleural pressure, measured via an esophageal tube.
30 t of positive-pressure-mediated increases in
intrapleural pressure.
31 irway pressures of approximately 7 mm Hg and
intrapleural pressures of approximately 3 mm Hg in both
32 A control dose of
intrapleural saline was administered after complete drai
33 In rabbits given
intrapleural single-chain urokinase 24 and 48 hours afte
34 Intrapleural siRNA delivery has considerable potential a
35 c motor neurons, and PKCtheta knockdown with
intrapleural siRNAs abolishes pLTF.
36 Intrapleural siRNAs targeting PKCzeta, an atypical PKC i
37 Intrapleural t-PA-DNase therapy improved fluid drainage
38 single-chain urokinase 24 and 48 hours after
intrapleural tetracycline (n = 10 animals), adhesions we
39 Intrapleural therapy using interferon gamma, particularl
40 study treatments for 3 days: double placebo,
intrapleural tissue plasminogen activator (t-PA) and DNa
41 s data have shown that the combination of an
intrapleural tissue plasminogen activator and deoxyribon
42 , 55 years; 44 male, 22 female) who received
intrapleural tPA between 2000 and 2006 was performed.
43 Intrapleural tPA is effective in improving drainage of l
44 ulation does not increase bleeding risk with
intrapleural tPA, but therapeutic anticoagulation is ass
45 To compare chest drain with
intrapleural urokinase and primary video-assisted thorac
46 is no difference in clinical outcome between
intrapleural urokinase and VATS for the treatment of chi
47 receive either percutaneous chest drain with
intrapleural urokinase or primary VATS.